Clinical trials: System Lupus Erythematosus
Lupus
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are…
- Trial name
- NCT00299819
- Testing
- MEDI-545, MEDI 545
- Where
- 21 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- MedImmune LLC
Systemic Lupus Erythematosus
A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus
A study of CM313 in subjects with systemic lupus erythematosus
- Trial name
- NCT05465707
- Testing
- CM313 2 mg/kg, CM313 4 mg/kg, CM313 8 mg/kg
- Volunteers
- 40 people
- Sponsor
- Keymed Biosciences Co.Ltd
Vitamin D Deficiency
Vitamin D Supplementation in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder. It mainly involves the skin, the joints, the nervous system and the kidney and may be life threatening.
- Trial name
- VITALUP (NCT01413230)
- Testing
- cholecalciferol
- Where
- 3 sites in France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lupus Nephritis, Mesenchymal Stem Cells
Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis
This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).
- Trial name
- NCT04318600
- Testing
- human amniotic mesenchymal stem cell
- Volunteers
- 16 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Lupus Nephritis, Remission
Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
The goal of this single-center, prospective clinical trial is to test the safety and efficacy of belimumab combined with multi-target therapy in the treatment of severe lupus nephritis.
- Conditions
- Lupus Nephritis, Remission, Safety Issues
- Trial name
- BEAM (NCT05863936)
- Testing
- Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanjing University School of Medicine
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
European Society of Cutaneous Lupus Erythematosus (EUSCLE)
Cutaneous lupus erythematosus (CLE) is a disease with a wide spectrum of clinical manifestations and a variable prognosis. The aim of the study is to create a standardized evaluation of the different subtypes of this disease in…
- Trial name
- NCT00420121
- Testing
- laboratory analysis
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- European Society of Cutaneous Lupus Erythematosus e.V.
Antiphospholipid Syndrome, Systemic Lupus Erythematosus
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.
- Conditions
- Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke
- Trial name
- RISAPS (NCT03684564)
- Testing
- Rivaroxaban, Warfarin
- Where
- 6 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- University College, London
Systemic Lupus Erythematosus, SLE (Systemic Lupus)
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).
- Conditions
- Systemic Lupus Erythematosus, SLE (Systemic Lupus), Autoimmune
- Trial name
- NCT05866861
- Testing
- CUG252
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cugene Inc.
Lupus Nephritis
Urinary G3BP as a Novel Biomarker in Lupus Nephritis
Estimation of urinary Galectin-3 binding protein (u-Gal-3BP) in patients with systemic lupus erythematosus with and without lupus nephritis and in glomerulonephritis for other kidney diseases, Find the relation of urinary…
- Trial name
- NCT06520670
- Testing
- Urinary galectin-3 binding protein
- Volunteers
- 70 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
The present study aims to: Compare clinical features, hematological indices and disease activity between the early-onset and late-onset patients with systemic lupus erythematosus.
- Trial name
- NCT06294483
- Testing
- CBC, Antinuclear Antibody tests (ANA), Rest of ANA profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Autoimmune Diseases, Systemic Lupus Erythematosus
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both sequentially in the treatment of Relapsed/ Refractory…
- Conditions
- Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome
- Trial name
- BAH247 (NCT06428188)
- Testing
- BCMA/CD19 CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Systemic Lupus Erythematosus
Nelfinavir in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease in which the body's immune system attacks different parts of the body.
- Trial name
- NISLE (NCT02066311)
- Testing
- Nelfinavir
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT03920267
- Testing
- BMS-986165
- Where
- 98 sites in United States, Argentina and 12 more
- Volunteers
- 261 people
- Sponsor
- Bristol-Myers Squibb
Lupus Erythematosus, Systemic
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT05203419
- Testing
- MHS552
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
- Trial name
- NCT05540665
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 10 more
- Volunteers
- 19 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus, Pregnancy Related
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age.
- Trial name
- NCT04976465
- Testing
- Anticoagulation, Without Anticoagulation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qilu Hospital of Shandong University
Lupus Nephritis, Proteinuria
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
- Conditions
- Lupus Nephritis, Proteinuria, CTX
- Trial name
- NCT00935389
- Testing
- tripterygium glycosides
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Nanjing University School of Medicine
Autoimmune, Lupus Erythematosus, Systemic
Effect of Green Tea on Treatment of Lupus
This randomized double blind clinical trial performed on 68 patients (32 in intervention and 36 in control group) diagnosed with SLE.
- Trial name
- NCT02875691
- Testing
- green tea extract
- Where
- Iran
- Volunteers
- 68 people
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
Systemic Lupus Erythematosus
Study of GL701 in Men With Systemic Lupus Erythematosus
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug meant to enhance DHEA levels.
- Trial name
- NCT00037128
- Testing
- GL701
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genelabs Technologies
Systemic Lupus Erythematosus, Physical Activity
Activity and Nutrition Trial in Lupus to Energize and Renew
Participants from the Fatigue and Lifestyle Physical Activity and SLE Study will be approached to enroll in a 6 week pilot intervention.
- Conditions
- Systemic Lupus Erythematosus, Physical Activity, Sleep
- Trial name
- ANTLER (NCT02281513)
- Testing
- Smartphone Application, Fitbit Activity Monitor, Coaching Sessions
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.